Phase 3 ASCEND Study of Pirfenidone in Idiopathic Pulmonary Fibrosis ... Stockhouse In ASCEND, pirfenidone significantly reduced decline in lung function as measured by change in percent predicted forced vital capacity (FVC) from Baseline to Week 52 (rank ANCOVA p<0.000001). Additionally, significant treatment effects were ... |
